Actinium Pharmaceuticals, Inc. (ATNM) Earnings History
Annual and quarterly earnings data from 2006 to 2024
Loading earnings history...
ATNM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ATNM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | 100.0% | -64098.8% | -60269.1% |
| 2022 | 100.0% | -3311.1% | -3205.5% |
| 2021 | 54.2% | -2182.2% | -2165.6% |
| 2020 | - | - | - |
Download Data
Export ATNM earnings history in CSV or JSON format
Free sign-in required to download data
Actinium Pharmaceuticals, Inc. (ATNM) Earnings Overview
As of May 8, 2026, Actinium Pharmaceuticals, Inc. (ATNM) reported trailing twelve-month net income of -$35M, reflecting +30.6% year-over-year growth. The company earned $-1.11 per diluted share over the past four quarters.
Looking at the long-term picture, ATNM's historical earnings data spans multiple years. The company achieved its highest annual net income of $10,289 in fiscal 2011.
Actinium Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RNAC (-$152M net income, -4658.6% margin), RAIN (-$6M net income), PHAT (-$127M net income, -126.3% margin), ATNM has comparable earnings metrics. Compare ATNM vs RNAC →
ATNM Earnings vs Peers
Earnings metrics vs comparable public companies
ATNM Historical Earnings Data (2006–2024)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$38M | +21.7% | -$42M | $-1.27 | - | - |
| 2023 | -$49M | -47.9% | -$52M | $-1.83 | -60269.1% | -64098.8% |
| 2022 | -$33M | -33.3% | -$34M | $-1.37 | -3205.5% | -3311.1% |
| 2021 | -$25M | -11.5% | -$25M | $-1.20 | -2165.6% | -2182.2% |
| 2020 | -$22M | -1.4% | -$22M | $-1.83 | - | - |
| 2019 | -$22M | +7.4% | -$22M | $-4.37 | - | - |
| 2018 | -$24M | +11.1% | -$24M | $-6.69 | - | - |
| 2017 | -$27M | -9.4% | -$27M | $-11.96 | - | - |
| 2016 | -$24M | -15.7% | -$27M | $-15.06 | - | - |
| 2015 | -$21M | +14.8% | -$25M | $-16.53 | - | - |
See ATNM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATNM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATNM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATNM — Frequently Asked Questions
Quick answers to the most common questions about buying ATNM stock.
Is ATNM growing earnings?
ATNM EPS is $-1.11, with earnings growth accelerating to +30.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-35M.
What are ATNM's profit margins?
Actinium Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ATNM's earnings?
ATNM earnings data spans 2006-2024. The accelerating earnings trend is +30.6% YoY. Historical data enables comparison across business cycles.